It demonstrated a systemic effect of the drug with decreased weight gain, improved insulin sensitivity (HOMA-IR, adiponectin), dyslipidemia (triglycerides and cholesterol) along with resolution of steatohepatitis and improvement in all of the key histological features of NASH. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.